Gov. Andrew Cuomo announced yet another series of reopening moves for New York on Monday, affirming that the iconic New York State Fair in Syracuse will be held in person this August and raising capacity limits on a number of core businesses, including outdoor stadiums, offices and fitness clubs.
There will be some planning modifications for the event, which typically draws people from 28 states and at least a half-dozen countries, the governor said. The 18-day fair will be spread across four dedicated areas — food and beverage, amusement rides, concerts and agriculture — to help manage the crowds. Cuomo said capacity will be limited to about 50 percent of the max for this year’s fair in August. Tickets will be sold independently for each of the four outdoor areas so families can decide in advance which ones they want to visit. Capacity limits will be reexamined and adjusted if necessary to comply with health and safety guidelines. The fairground’s buildings will not be open to the public, except for bathrooms.
Johnson & Johnson’s COVID-19 Vaccine Appears Poised for Another Green Light
With few additional cases of rare and serious blood clots seen over the last several days, health officials in the United States are expected to recommend the resumption of Johnson & Johnson’s COVID-19 vaccine rollout.Resumption of the shot will likely come with a warning about the unusual side effect which has stricken roughly one in every million of those who have received the vaccine, The New York Times reports.A working group of experts assembled by the Centers for Disease Control and Prevention will review data today and make their recommendation to the FDA.
When the group met last Wednesday, it reported six cases and one death among the 7.2 million recipients of the vaccine. At the time, the group decided to extend the pause of the shot to gather more data.Since then, only a few additional cases have been reported. The FDA declined to divulge how many to the New York Times.“We’ve now received more cases, but it isn’t an avalanche,” FDA acting director Janet Woodcock said on Thursday. “We’re not seeing a big surge, which is a great relief.”